Biotech
-
Bristol Myers’ $11.1 Billion Bet on BioNTech: Is Oncology The New Growth Engine?
Bristol Myers has inked a transformative partnership for BNT327, a bispecific PD-L1/VEGF-A antibody developed by BioNTech, with a $1.5 billion…
Read More » -
Eli Lilly’s $1 Billion Bet On SiteOne: Can Non-Opioid Pain Drugs Reshape The Pharma Giant’s Future?
Eli Lilly has agreed to acquire SiteOne Therapeutics, a clinical-stage biotech specializing in small molecule inhibitors of sodium channels involved…
Read More » -
Aspire Biopharma CEO Interview: Disrupting Drug Delivery with Sublingual Tech
SmallCaps Daily sits down with ASBP’s CEO Kraig Higginson to discuss the company's disruptive technology and the expected clinical and…
Read More » -
Is Cytokinetics The Next Big Takeover Target? Here’s What You Need to Know!
Cytokinetics has recently surged amid renewed takeover speculation as reported on a Betaville "uncooked" alert, with multiple large pharmaceutical firms…
Read More » -
Arcutis Biotherapeutics Surges Amid Takeover Speculation: Why Large Pharma Should Pay Attention!
According to a Betaville "uncooked" alert, an unidentified European pharmaceutical company is reportedly exploring a bid for Arcutis Biotherapeutics.
Read More » -
Legend Biotech: Why The Recent Takeover Speculation Is Worth Your Attention!
Legend Biotech has drawn significant attention recently due to rumors of a potential takeover, with a 4% surge in its…
Read More » -
The Biotech Stock Soaring 63% on Unprecedented Cancer Trial Results – Meet Janux Therapeutics
On December 3, 2024, the company announced groundbreaking results for its lead drug candidate, JANX007, a tumor-activated T-cell engager targeting…
Read More » -
Why Maravai LifeSciences Could Be a Perfect Acquisition Target for Repligen
Maravai LifeSciences has recently caught the attention of Repligen as a potential acquisition target, marking it as a significant player…
Read More » -
SmallCaps Daily Sits Down with Milton Werner, President and CEO of Inhibikase Therapeutics
CEO and President, Milton Werner shares Inhibikase's vision, achievements, and future endeavors in neurological diseases while highlighting the significant progress…
Read More » -
Travere’s Recent Breakthrough Drug Sends Its Stock Soaring: What Investors Need To Know Now!
Travere Therapeutics' completion of a successful pre-NDA meeting with the U.S. FDA for Filspari in IgA nephropathy has sent its…
Read More »
